Department of Oral Mucosal Diseases, Shangehai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
National Clinical Research Center for Oral Diseases, Shanghai, China.
J Dermatolog Treat. 2022 Feb;33(1):550-554. doi: 10.1080/09546634.2020.1771258. Epub 2020 Jun 23.
Tacrolimus is a new type immunosuppressant. The aim of this study was to evaluate the effectiveness of topical tacrolimus 0.1% ointment at 2 different frequencies in treating patients with exfoliative cheilitis.
A total of 40 patients with exfoliative cheilitis were randomly divided into the QD group receiving topical tacrolimus 0.1% ointment once a day or the QOD group receiving topical tacrolimus 0.1% ointment once-two-day. Patients were also applied wet dressing of saline twice a day. The effectiveness of treatment was defined as the percentage of improvement in signs or symptoms.
37 patients completed the 2-week treatment. And, a full set was analyzed. The effectiveness of topical tacrolimus 0.1% ointment for relief in objective sign and subjective symptom was 50% and 67.5%% in the QD group, respectively. For the QOD group, the effectiveness of sign and symptom relief was 50% and 73.5%. There was no significant difference of effectiveness between application topical tacrolimus once a day and once 2 days.
Our data suggested that application of topical tacrolimus 0.1% ointment once a day and once 2 days had similar clinical effectiveness for sign and symptom relief in patients with exfoliative cheilitis.
他克莫司是一种新型免疫抑制剂。本研究旨在评估他克莫司 0.1%软膏两种不同频率在治疗剥脱性唇炎患者中的疗效。
共 40 例剥脱性唇炎患者随机分为 QD 组（每天接受他克莫司 0.1%软膏 1 次）和 QOD 组（每两天接受他克莫司 0.1%软膏 1 次）。两组患者均每天两次应用盐水湿敷。治疗的有效性定义为体征或症状改善的百分比。
37 例患者完成了 2 周的治疗。并对全部病例进行了分析。QD 组患者客观体征和主观症状缓解的有效率分别为 50%和 67.5%，QOD 组患者的有效率分别为 50%和 73.5%。每天应用他克莫司和每两天应用他克莫司的疗效无显著差异。
我们的数据表明，每天应用和每两天应用他克莫司 0.1%软膏在缓解剥脱性唇炎患者的体征和症状方面具有相似的临床疗效。
